Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nano-X Imaging Ltd.NNOX · Entity 7098 | GM Source & Services Division | October 11, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nano-X Imaging Ltd.
Report date October 11, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 28,283 |
Reported balance
After 2026-10-11 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-10-11 · Grant · Acquired 28,283 · Balance 28,283 F1: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 28,283 ordinary shares represented by 28,283 restricted share units ("RSUs"), pursuant to the Issuer's 2019 Equity Incentive Plan. F2: The 28,283 RSUs reported in this row vest and settle for underlying ordinary shares in four equal semi-annual installments of 25% each following the vesting commencement date of August 13, 2026-- on February 13, 2027, August 13, 2027, February 13, 2028 and August 13, 2028-- subject, in each case, to the Reporting Person's continuous employment by the Issuer as of the applicable vesting date, such that by the two-year anniversary of the vesting commencement date (August 13, 2028), all underlying shares will be issued to the Reporting Person. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 39,474 |
Reported balance
Holding disclosure · report date 2026-10-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 39,474 F3: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F4: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer on February 5, 2026, of which 50% vest and settle for underlying ordinary shares on the 12-month anniversary of the grant date (February 5, 2027) and the remaining 50% on the 24-month anniversary of the grant date (February 5, 2028). |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $49.68 · Expires 2031-01-18 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2026-10-11 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 100,000 F3: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F5: The options reported in this row were granted to the Reporting Person by the Issuer on January 18, 2021 and are fully vested and exercisable as of the date of this report. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $17.63 · Expires 2032-03-28 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2026-10-11 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 25,000 F3: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F6: The options reported in this row were granted to the Reporting Person by the Issuer on March 28, 2022 and are fully vested and exercisable as of the date of this report. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $17.63 · Expires 2032-08-11 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2026-10-11 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 10,000 F3: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F7: The options reported in this row were granted to the Reporting Person by the Issuer on August 11, 2022 and are fully vested and exercisable as of the date of this report. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $11.52 · Expires 2033-05-23 | Direct | 55,000 |
Reported balance
Holding disclosure · report date 2026-10-11 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 55,000 F3: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F8: The options reported in this row were granted to the Reporting Person by the Issuer on May 23, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable by the four-year anniversary of the grant date (May 23, 2027). |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 28,283 ordinary shares represented by 28,283 restricted share units ("RSUs"), pursuant to the Issuer's 2019 Equity Incentive Plan.
F2: The 28,283 RSUs reported in this row vest and settle for underlying ordinary shares in four equal semi-annual installments of 25% each following the vesting commencement date of August 13, 2026-- on February 13, 2027, August 13, 2027, February 13, 2028 and August 13, 2028-- subject, in each case, to the Reporting Person's continuous employment by the Issuer as of the applicable vesting date, such that by the two-year anniversary of the vesting commencement date (August 13, 2028), all underlying shares will be issued to the Reporting Person.
F3: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
F4: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer on February 5, 2026, of which 50% vest and settle for underlying ordinary shares on the 12-month anniversary of the grant date (February 5, 2027) and the remaining 50% on the 24-month anniversary of the grant date (February 5, 2028).
F5: The options reported in this row were granted to the Reporting Person by the Issuer on January 18, 2021 and are fully vested and exercisable as of the date of this report.
F6: The options reported in this row were granted to the Reporting Person by the Issuer on March 28, 2022 and are fully vested and exercisable as of the date of this report.
F7: The options reported in this row were granted to the Reporting Person by the Issuer on August 11, 2022 and are fully vested and exercisable as of the date of this report.
F8: The options reported in this row were granted to the Reporting Person by the Issuer on May 23, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable by the four-year anniversary of the grant date (May 23, 2027).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 11, 2026 Filed Oct 13, 2026 13:12 UTC | Nano-X Imaging Ltd. NNOX · Entity 7098 | GrantOrdinary Shares | 28,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-108784 · ownership.xml · nonDerivative · entry 1 Dara James · CIK 0002049065 · GM Source & Services Division 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,283 F1 · kind: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 28,283 ordinary shares represented by 28,283 restricted share units ("RSUs"), pursuant to the Issuer's 2019 Equity Incentive Plan. F2 · balance_after: The 28,283 RSUs reported in this row vest and settle for underlying ordinary shares in four equal semi-annual installments of 25% each following the vesting commencement date of August 13, 2026-- on February 13, 2027, August 13, 2027, February 13, 2028 and August 13, 2028-- subject, in each case, to the Reporting Person's continuous employment by the Issuer as of the applicable vesting date, such that by the two-year anniversary of the vesting commencement date (August 13, 2028), all underlying shares will be issued to the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.